Streetbeat News

Stock Prices

EOG

EOG Resources (NYSE:EOG) has seen a 9.92% decrease in short interest, with 6.35 million shares sold short, representing 1.09% of available shares. The average time to cover these short positions is 2.59 days. A decrease in short interest can indicate a more bullish sentiment towards the stock. EOG has less short interest compared to its peers, with an average of 6.34% short interest as a percentage of float in its peer group.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:15 pm

AUVI

BCDA

INVO

KBNT

SKIN

THRX

U.S. stocks traded higher with the Dow Jones gaining around 500 points. Real estate shares surged by 4.6%, while energy shares rose by 0.2%. The U.S. annual inflation rate decreased to 3.2% in October. BioCardia, Inc. (BCDA) soared 206% after FDA approval for a Phase 3 clinical trial. INVO Bioscience, Inc. (INVO) rose 28% after posting a narrower Q3 loss. Theseus Pharmaceuticals, Inc. (THRX) gained 50% after announcing a strategic alternatives exploration process. The Beauty Health Company (SKIN) plunged 60% due to weak Q3 results and a suspended 2025 forecast. Kubient, Inc. (KBNT) dropped 51% after announcing a voluntary delisting from Nasdaq. Applied UV, Inc. (AUVI) fell 44% after pricing a public offering. Oil and gold prices increased.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 6:11 pm

MRVL

Marvell Technology's stock (MRVL) is trading higher following a Buy rating initiation and a $60 price target from Roth MKM.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 6:08 pm

SPY

Fed's Goolsbee comments on the October CPI report, stating it 'looked pretty good' and acknowledges the 'very real pain' caused by inflation.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 6:08 pm

AGTI

Agiliti Inc.'s stock (AGTI) is trading higher following an upgrade from UBS, which changed its rating from Neutral to Buy. However, UBS also reduced its price target for Agiliti from $16 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 6:03 pm

VRDN

Over the past 3 months, 7 Wall Street analysts have provided ratings on Viridian Therapeutics (NASDAQ:VRDN), with 2 being bullish and 5 somewhat bullish. The average price target is $37.29, which is significantly higher than the current price of $14.3, suggesting a substantial upside. However, this target is a 13.28% decrease from the previous target of $43.00.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:01 pm

ALXO

ALX Oncology Holdings (NASDAQ:ALXO) received 7 analyst ratings in the last quarter, with an average 12-month price target of $17.79, a high of $27.00, and a low of $10.00. The current average price target represents an 8.48% increase from the previous average of $16.40. The distribution of ratings was 3 bullish, 4 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. Analysts typically rate stocks each quarter based on various research methods and their ratings reflect their opinions on the stock.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:01 pm

AMAM

Ambrx Biopharma (NASDAQ:AMAM) has received 7 analyst ratings in the last quarter with an average price target of $23.71, which is significantly higher than its current price of $8.88. The consensus among analysts appears to be positive, with 1 bullish and 5 somewhat bullish ratings. The average price target has increased by 4.59% from the previous target of $22.67.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:01 pm

DKS

Over the past 3 months, 17 Wall Street analysts have provided ratings for Dick's Sporting Goods (NYSE:DKS), with an average price target of $132.88, which is an implied upside from the current price of $112.48. The consensus among these analysts is leaning towards a bullish and somewhat bullish stance, with 1 bullish, 6 somewhat bullish, and 10 indifferent ratings. Notably, the current average price target has decreased by 15.04% from the previous target of $156.40.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:01 pm

OBDC

Over the past 3 months, 4 Wall Street analysts have rated Blue Owl Capital (NYSE:OBDC) as somewhat bullish with an average price target of $15.5, which is higher than the current price of $14.55. All 4 analysts have maintained this rating over the period, with the latest rating coming in the last 30 days. The average price target represents an implied upside and has increased by 3.33% over the past month.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 6:00 pm